Summit Therapeutics PLC (NASDAQ:SMMT)‘s stock had its “buy” rating reaffirmed by equities researchers at Oppenheimer Holdings Inc. in a report issued on Wednesday. Separately, Zacks Investment Research raised Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, February 3rd. […]
